Alice Rigby
View profile
Updated 01 Jun 2023
Save Article Download

Disclaimer

Disclosure – Non-Independent Marketing Communication

This is a non-independent marketing communication commissioned by International Biotechnology. The report has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on the dealing ahead of the dissemination of investment research.

Over the last two years, the biotechnology sector has suffered. The emergence from the COVID pandemic was particularly painful as the trend-led support for the sector melted away amid a broader storm for equities. The NASDAQ Biotechnology Index has only just returned to the valuation it saw three years ago, following a 30% rise in 2021 and subsequent plummet in 2022.

However, some promising data is emerging for the sector. The most notable is a marked rise in the value of both M&A deals and IPOs coming to market in the first four months of this year and, in the case of M&A, throughout 2022 according to data compiled by Biopharmadive, after a stunted period for both across 2020 and 2021 due to COVID-19 restrictions and overheated valuations.

It is also notable that the bear market for biotechnology stocks has gone on longer than in any previous cycle. Although this should not be read as an indicator in isolation, combined with the deal data coming through it is suggestive of a market on the precipice of a new stage.

On solid ground

The team behind 12-month sector-leading trust, International Biotechnology Trust (IBT), have developed a distinct methodology for distinguishing where we are in the biotechnology valuation cycle. Their five stage cycle identifies the signals that show progression through each stage and helps indicate where co-lead managers, Ailsa Craig and Marek Poszepczynski, could seek opportunities.

The promising trends emerging in the first half of this year have led Ailsa and Marek to be cautiously optimistic, suggesting that the sector has reached an early ‘equilibrium’ stage; although they say it is worth remembering that biotechnology still rides the waves of the broader equity market and can therefore be impacted by trends within it, such as the banking crisis earlier in the year which was challenging for some earlier stage biotechnology valuations. These challenges also mean that generalist investors are still largely staying away from the sector.

Nonetheless, the changing context for biotechnology has prompted Ailsa and Marek to begin evolving the portfolio for a new stage in the cycle.

Earlier this year, we discussed how they were focusing on the kind of revenue-generating mid-caps that were key targets for larger-cap firms in the “recovery” stage of the cycle. While these kinds of companies remain a key part of the portfolio mix, with the patent expiration cliff edge meaning plenty of merger activity is expected in this area, Ailsa and Marek have begun to look further down the capitalisation spectrum to find new homes for the cash received from M&A deals in the portfolio.

Treading carefully among smaller caps

Given that risks remain for the sector, they are being very selective when allocating to smaller, riskier companies. One strategy is to focus on companies that have just been through a binary event – for example a clinical trial – as typically the next binary event will be some way off. At this stage, valuations are less impacted by investors seeking to make short-term profits off the outcome of these types of events.

Another tactic the pair apply is to avoid the most crowded markets, where too many businesses are trying to solve the same problem. In this early stage science, it can be challenging to determine which solutions will ultimately be successful, either from a scientific or commercial perspective. Instead, they focus on areas where technologies are broadly maturing and key players are already emerging, such as in gene therapies where they have made several investments.

As ever, Ailsa and Marek also seek businesses meeting unmet medical needs which are well-run and well-financed, with management and ownership structure particularly relevant for businesses of this size.

The outlook for biotechnology is brightening. Though further clouds could still colour the horizon, the IBT team is responding to the positive news cycle by slowly, carefully adding smaller companies to their portfolio. Crucially, this fits into their long-held investment strategy, which focuses on generating long-term growth while managing portfolio risk.

Login to read the full article...

Kepler Trust Intelligence provides research and information for professional and private investors. In order to ensure that we provide you with the right kind of content, and to ensure that the content we provide is compliant, you need to tell us what type of investor you are.

Continue

Welcome to Kepler Trust Intelligence

Please enter a valid email address
{{item.msg}}
Please enter a valid password
{{item.msg}}
Please enter a valid email address
{{item.msg}}
Please check your email. If an account exists you'll be sent instructions on how to reset your password.
To ensure that we are able to provide content which is appropriate for you, please tell us a little about yourself.
Please choose an option
{{item.msg}}
Please enter a company name
{{item.msg}}
Please enter a location name
{{item.msg}}
Please choose an option
{{item.msg}}
Please enter a platform
{{item.msg}}
Please choose an option
{{item.msg}}
Please enter a trust
{{item.msg}}
See benefits
A free Kepler Trust Intelligence account allows you to access premium content including the ‘Kepler View’ – our verdict on the trusts we cover – and historical research so you can see how our view has changed over time. An account also unlocks useful facilities like the ‘follow’ button which lets you keep track of the trusts you’re interested in and as a logged in user you can also download PDFs of our research, and choose the layout of the page you’re reading to suit your preference. We will not share your details unless you give us permission to do so, and we won’t bombard you with emails – we only send one a week.
Please select an option
{{item.msg}}
Please enter your first name
{{item.msg}}
Please enter your last name
{{item.msg}}
Please enter a valid email address
An account already exists with this email - have you forgotten your password?
{{item.msg}}
Please enter a valid password
{{item.msg}}
Please enter a valid password
{{item.msg}}
?
The information contained herein is not for distribution and does not constitute an offer to sell or the solicitation of any offer to buy any securities in the United States to or for the benefit of any United States person (being residents of the United States or partnerships or corporations organised under the laws thereof). The investment funds referred to herein have not been registered in the United States under the Investment Company Act of 1940 and units or shares of such funds are not registered in the United States under the Securities Act of 1933.
Please confirm
{{item.msg}}
Please select an option
{{item.msg}}
How will this information be used? Your answers help us to tailor our content to relevant investment trusts, and to ensure that the asset allocation and portfolio strategy research we produce is appropriate to our userbase.
Our Website uses Cookies Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean we can understand how you use our site. Some cookies have already been set. You can delete and block cookies, but parts of our site won’t work without them. By using our website you accept our use of cookies. For further information please refer to the Kepler Privacy Notice.
Need help?

One more thing...

Did you know, you can 'follow' individual trusts on Kepler Trust Intelligence? Use the functions below to set up alerts and we'll send you research and updates on your chosen trusts.

Suggested trusts to follow

Browse all funds
Need help?
Current Site Kepler Trust Intelligence is produced by the investment companies team at Kepler Partners and is the UK’s premier source of detailed qualitative research on investment trusts. Absolute Hedge is a market leading UCITS research database providing proprietary research on funds, themes and strategies in the UCITS space. Kepler Liquid Strategies is a Dublin domiciled UCITS fund platform featuring a number of best-of-breed fund managers. Kepler Partners is a corporate advisory and asset raising boutique specialising in the regulated funds market in Europe and investment trusts in the UK.